ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 460,800 shares, a drop of 20.6% from the March 31st total of 580,600 shares. Approximately 6.1% of the company’s shares are short sold. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is currently 0.2 days.

ZyVersa Therapeutics Trading Down 17.9 %

Shares of ZVSA stock opened at $4.99 on Monday. The business’s 50 day moving average is $7.64 and its two-hundred day moving average is $14.49. ZyVersa Therapeutics has a 12 month low of $4.44 and a 12 month high of $220.85.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of ZyVersa Therapeutics in a research report on Tuesday, March 26th.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.